ClinicalTrials.gg
Not yet recruitingNCT07291102Updated Oct 20, 2026

Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma

A Phase 3 interventional study of Bridging Chemotherapy and Induction Cycles A1-A3 in Medulloblastoma, sponsored by Nationwide Children's Hospital. Not yet recruiting at 2 sites in United States. Open to participants aged Up to 5 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Nationwide Children's Hospital · Phase 3, Interventional, and Treatment

How we know

Updated Oct 20, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
Up to 5 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 245 studies in Medulloblastoma with a site in United States — 26 open to participants now, 53 under way, 2 of them phase 3. Medulloblastoma · United States.

Planned enrollment
32nd of 215
96 · median 30
Started
2027
the only one that year
Phase 3
11 of 245
2 open now
Primary completion
2034-10
later than 48 of 52 live
Registered
239th of 245
by date

Among the 245 studies in Medulloblastoma with a site in United States, this one is the 32nd largest by planned enrollment of the 215 interventional ones that give a count, is the only one that started in 2027, is one of 11 in phase 3, reaches primary completion later than 48 of the 52 other live ones, and was the 239th registered.

Medulloblastoma

317 studies on the registry are indexed under Medulloblastoma; 52 are open to participants now.

Browse Medulloblastoma studies →

Open to participants now

26 of the 245 studies in Medulloblastoma with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 38 Medulloblastoma studies recruiting now, 4 (11%) set no upper age limit and 32 (84%) stop at 75 or younger; 35 take children under 18; 1 takes healthy volunteers.

This study: Up to 5 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 245 studies in Medulloblastoma with a site in United States, or all of them as a file.
02

Study summary

This is a trial to compare neurocognitive outcomes in the intent-to-treat population 2.5 years after diagnosis between patients with newly diagnosed, non-metastatic, SHH-activated, TP53-wt, non-MYC amplified MF randomized to the interventional arms A ("Head Start 4") or B (HIT-SKK).

Read the detailed description

In this study, two highly effective irradiation-sparing treatment regimens are being compared in patients with low-risk early childhood MB:

  1. Arm A: The "Head Start" 4 regimen developed by the North American Head Start Consortium. This approach uses intensive Induction chemotherapy and Consolidation with HDCT and has led to equally favorable results in this subgroup -- 3y PFS was 96% for infants and young children with M0, SHH MB; 5y EFS was 93% for M0, DMB on the predecessor "Head Start" 3 study.
  2. Arm B: The HIT-SKK regimen developed within the GPOH. This regimen combines systemic chemotherapy with intraventricular MTX, leading to 93% 5-year PFS in low-risk patients.

Both treatment regimens use high-dose i.v. MTX, but only the HIT-SKK regimen also uses intraventricular administration of MTX directly into the CSF in addition to i.v. MTX. Given the long-term neurocognitive deficits of MTX have been described in childhood leukemia, and the pathogenesis of MTX-induced CNS-damage has been described, this has raised some concerns. Similarly, highly intensive, HDCT containing "Head Start" chemotherapy carries specific risks for the neurocognitive outcomes. Encouragingly, five years after HIT-SKK treatment including intraventricular MTX, young children with MB have a mean fluid intelligence score of 93.8 points. The full-scale IQ after "Head Start" chemotherapy is 95.4 and likewise within normal range. On the other hand, highly intensive, HDCT/AuHCR containing "Head Start" chemotherapy carries specific risks for the neurocognitive outcomes. However, neurocognitive outcomes after the HIT-SKK and "Head Start" chemotherapy regimens are difficult to compare from existing data, because of small sample sizes and inhomogeneous assessment tools used in prior studies. Therefore, a confirmatory study utilizing the same measures administered at the same time points is required to identify clinically relevant differences. In addition, survival, occurrence of second malignancies, neurological and endocrine deficits, hearing loss, and psychosocial comorbidities are also of high relevance in survivors of MB and may differ after both regimens. Since these also severely limit the survivors' potential for activity and participation in everyday life and affect their parents and siblings as well, this information will also be recorded.

03

Conditions studied

  • Medulloblastoma

Browse trials for

04

Who can participate

Ages eligible
Up to 5 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria for screening:

  • Age at diagnosis \< 5 years
  • Patients with institutional suspicion or diagnosis of SHH-activated MB
  • Patient and family in social circumstances that will allow neuropsychological follow-up
  • Ability of parents/legal representatives to understand the patient information and to personally sign and date the to participate in screening procedures
  • Patient and the parents/legal representative are able and willing to participate in the entire study (if patient is eligible)

Exclusion Criteria for overall study:

  • Patients previously treated for any other brain tumor or any type of malignant disease
  • Patients, in whom compliance with toxicity management guidelines and study procedures cannot be assured
  • History of to an medicinal product or to any drug with similar chemical structure or to any present in the pharmaceutical form of an investigational medicinal product.
  • Patients/parents who do not wish to abstain from treatment with during study participation
  • Patients with a language barrier too extensive to complete neuropsychological tests based on the investigator's judgement
  • Patients with severe premorbid developmental delay (based on the investigator's judgement), which will not allow WPPSI-IV assessment after 2.5 years
  • Patients cannot undergo MRI

Inclusion Criteria for Bridging chemotherapy (carboplatin/etopiside) in interventional arms:

  • Patients with SHH-activated MB, TP53-wt demonstrated by IHC for Gab1 or p75-NGFR, Yap1, beta-catenin, and TP53 (lack of strong and widespread nuclear p53 positivity) on central review according to WHO classification 2021.
  • No clinical evidence of extra-
  • Negative CSF cytology
  • No prior therapy for MB other than surgery
  • No other medical to chemotherapy:
  • No uncontrolled invasive fungal infection or other severe systemic infection requiring system/parental therapy
  • No other severe organ dysfunctions, which cannot be clinically controlled
  • No concomitant use with yellow fever vaccine and with live virus and bacterial vaccines
  • No demyelinating form of Charcot-Marie-Tooth syndrome
  • Assessment of hearing function completed
  • No evidence of cancer predisposition syndromes other than Gorlin syndrome or ELP1, GPR161 germline alterations.
  • Provided written informed consent by parent(s)/parent representative(s) by bridging chemotherapy
  • Patient should be enrolled within 28 days after diagnosis. Bridging chemotherapy can start as early as criteria for enrollment are met, and must start no later than 33 days after diagnosis

Exclusion Criteria for bridging chemotherapy:

  • One or more of the inclusion criteria for bridging chemotherapy are lacking
  • Other histology than SHH MB

Inclusion Criteria for randomization:

  • Patient has received bridging chemotherapy as described in this protocol
  • Patients with centrally reviewed SHH-activated MB, TP53-wt, according to WHO classification 2021
  • Absence of disease on central radiology review
  • Exclusion of TP53-mutation by DNA sequencing of the TP53-gene from tumor tissue by central review. Results from local institution will be accepted if raw data of this analysis is forwarded to the national central review institution
  • Confirmation of SHH activation by DNA methylation-based classification on central review. Results from local institution will be accepted if raw data of this analysis is forwarded to the national central review institution
  • No amplification of MYC (amplification of MYCN allowed). Array-based technologies (850k array, molecular inversion probe assay (MIP)), array-based comparative genomic hybridization (array-CGH) or next generation sequencing (NGS) DNA sequencing coverage MYC locus will be used. If these alternative assays give any indication of possible amplification, FISH will be performed on central review.
  • No other medical contraindications to chemotherapy:
  • No uncontrolled invasive fungal infection or other severe systemic infection requiring system/parental therapy
  • No other severe organ dysfunctions, which cannot be clinically controlled
  • No concomitant use with yellow fever vaccine and with live virus and bacterial vaccines
  • No demyelinating form of Charcot-Marie-Tooth syndrome
  • Retrospective assessment of pre-operative health-related QoL (HR-QoL) measured by Pediatric Quality of Life Inventory
  • Provided written informed consent by parent(s)/parent representative(s) for randomization

Exclusion criteria for randomization:

-Patients are excluded from the interventional study if any of the following criteria are met:

  1. One or more of the inclusion criteria for randomization are lacking
  2. Patients with metastatic disease
  3. TP53-mutated SHH MB
  4. MYC amplified MB
  5. Pre-existing condition incompatible with scheduled therapy (e.g. Fanconi anemia)
  6. Patients with non-communicating hydrocephalus, e.g. due to perinatal intracranial haemorrhage, adueductal stenosis, or meningitis
  7. Contraindication for any components of the randomized therapies, including HDCT and intraventricular chemotherapy. Note: postperative hydrocephalus is not a contraindication for i.ventr. MTX.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    Arm A: "Head Start" 4

    Arm A consists of 3 to 5 Induction chemotherapy cycles and one high-dose chemotherapy cycle evaluated in the "Head Start" 4 study.

    Drug: Bridging Chemotherapy · Drug: Induction Cycles A1-A3 · Drug: Induction Cycles A4-5 · Drug: Consolidation Cycle A6

  • Experimental
    Arm B: HIT-SKK

    Arm B consists of 3 to 5 cycles of chemotherapy evaluated in the HIT-SKK'92 (Rutkowski et al. 2005) and HIT-2000 (NCT00303810) clinical studies.

    Drug: Bridging Chemotherapy · Drug: HIT-SKK Chemotherapy Cycles B1-3 · Drug: Modified HIT-SKK Cycle B4-5

Interventions

  • DrugBridging Chemotherapy

    One bridging chemotherapy cycle consists of five days of therapy using Carboplatin and etoposide

  • DrugInduction Cycles A1-A3

    Cisplatin, vincristin, etoposide, cyclophosphamide, high-dose methotrexate

  • DrugInduction Cycles A4-5

    Cisplatin, etoposide, cyclophosphamide, high-dose methotrexate

  • DrugConsolidation Cycle A6

    Carboplatin, thiotepa, etoposide

  • DrugHIT-SKK Chemotherapy Cycles B1-3

    Cyclophosphamide, vincristine, high-dose methotrexate, carboplatin, etoposide, i.ventri. methotrexate

  • DrugModified HIT-SKK Cycle B4-5

    Cyclophosphamide, vincristine, carboplatin, etoposide

06

What researchers measure

Primary outcomes

  1. Neurocognitive Outcomes using WPPSIIV

    To compare neurocognitive outcomes 2.5 years after diagnosis between patients randomized to the interventional arms A ("Head Start" 4) and B (HIT-SKK). Full-Scale Intelligence Quotient (IQ) as measured by the Wechsler Preschool and Primary Scale of Intelligence (WPPSIIV) administered to those between the ages of 2 years and 6 months to 7 years and 7 months old at 2.5 years after diagnosis (+/- 6 months).

    Time frame: 105 months

Secondary outcomes

  1. PFS

    Progression-free survival (PFS) compared between randomized groups

    Time frame: 152 months

  2. rtPFS

    Radiotherapy-free/progression-free survival (rtPFS) compared between randomized groups

    Time frame: 152 months

  3. OS

    Overall survival (OS) compared between randomized groups

    Time frame: 152 months

  4. Second malignancies

    Incidence of second malignancies compared between randomized groups

    Time frame: 152 months

  5. Number of patients with treatment-related adverse events as assessed by CTCAE v5.0

    Acute toxicities compared between randomized groups

    Time frame: 152 months

  6. Incidence of therapy-related deaths

    Incidence of therapy-related deaths compared between randomized groups

    Time frame: 152 months

  7. Assessment of IQ in patients randomized to Head Start or HIT-SKK

    Wechsler Intelligence Scale for Children (WISC-V) Full Scale IQ at 5 years after diagnosis (+/- 12 months range allowed), with the Wechsler Preschool and Primary Scale of Intelligence (WPPSI) Full Scale IQ Score used only for children \< 6 years old.

    Time frame: 152 months

  8. Assessment of Development and Adaptive Functioning using ABAS v2 or v3

    Adaptive Behavior Assessment System (ABAS, versions II or 3) at diagnosis, 2.5- and 5 years after diagnosis will be used to compare patients randomized to Head Start or HIT-SKK.

    Time frame: 152 months

  9. Quality of Life Assessment using PedsQL Infant or PedsQL 4.0 parent-reported Quality of Life Measure

    PedsQL Infant or PedsQL 4.0 parent-report QoL measure depending upon current age at the treatment timepoints. Questionnaires are quantified on a scale of 0-100 where higher scores indicate better outcomes/quality of life.

    Time frame: 152 months

  10. Correlation between neurocognitive outcomes and QoL

    Correlation of neurocognitive outcomes (measured using WISC-V Full Scale IQ at 5 years after diagnosis) and quality of life (measured using PedsQL Infant) 5 years after diagnosis will be achieved using a regression for linear mixed model.

    Time frame: 152 months

  11. Assessment of impact on hearing using SIOP Boston scale

    Ototoxicity will be assessed through hearing evaluation according to SIOP Boston scale (patients with normal Distortion-Product Otoacoustic Emissions (DPOAE) will be considered as not having hearing loss).

    Time frame: 152 months

  12. Number of patients with Leukoencephalopathy

    LEP will be assessed 2.5 and 5 years after diagnosis compared between randomized groups using the modified Fazekas scale.

    Time frame: 152 months

  13. Compare PFS

    To compare PFS between randomized groups in patients in CR at end of study therapy

    Time frame: 152 months

  14. Compare PFS

    To compare PFS between subtypes of SHH-MB as defined by classification based on the Heidelberg brain tumor classifier Version 11 (or higher)

    Time frame: 152 months

  15. Assess rate of patients with cancer predisposition syndromes

    To assess the rate of patients with genetically confirmed basal cell nevus syndrome (BCNS, Gorlin-Syndrome, OMIM: 109400), ELP1 and GPR161 cancer predisposition syndromes among eligible enrolled patients

    Time frame: 152 months

  16. Compare rtPFS

    To compare rtPFS between subtypes of SHH-MB as defined by classification based on the Heidelberg brain tumor classifier Version 11 (or higher)

    Time frame: 152 months

  17. Compare OS

    To compare OS between subtypes of SHH-MB as defined by classification based on the Heidelberg brain tumor classifier Version 11 (or higher)

    Time frame: 152 months

  18. Compare rtPFS

    To compare rtPFS between randomized groups in patients in CR at end of study therapy

    Time frame: 152 months

  19. Compare OS

    To compare OS between randomized groups in patients in CR at end of study therapy

    Time frame: 152 months

  20. Assessment of impact on hearing using Chang scales

    Ototoxicity will be assessed through hearing evaluation according to Chang Scale (patients with normal Distortion-Product Otoacoustic Emissions (DPOAE) will be considered as not having hearing loss).

    Time frame: 152 months

  21. Association between neurocognitive and behavioral outcomes

    Association of neurocognitive (measured using WISC-V Full Scale IQ at 5 years after diagnosis and WPPSI Full Scale IQ Score used only for children \< 6 years old) outcomes and behavioral outcomes (measured using ABAS v2 or v3) 5 years after diagnosis compared between randomized groups

    Time frame: 152 months

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: Yes — This study is considered for publication in the scientific literature in a peer re-viewed journal, irrespective of the results. Study results may also be presented at one or more medical congresses and may be used for scientific exchange and teaching purposes. Additionally, this study and its results may be submitted for inclusion in all appropriate health authority study registries, as well as publication on health authority study registry websites, as required by local health authority regulations.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Jan 2027; primary completion for Oct 2034, 93 months later.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Jan 2027, on Oct 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2025
First posted
Dec 18, 2025
StartEst.
Jan 1, 2027was Jul 2026
Primary completionEst.
Oct 2034
CompletionEst.
Oct 2038
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jul 1, 2026→Jan 1, 2027
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Start date Jul 1, 2026→Jan 1, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07291102
Collaborators
German Society of Paediatric Oncology and Hematology (GPOH gGmbH), Children's of Alabama
Responsible party
Sponsor
First posted
Dec 18, 2025
Start date
Jan 1, 2027 (estimated)
Primary completion
Oct 2034 (estimated)
Completion
Oct 2038 (estimated)
Last update
Oct 20, 2026

Study contacts

Kelsey Troyer, PhD
Contact
kelsey.troyer@nationwidechildrens.org
16147228566
Maryam Fouladi, MD
principal investigator · Nationwide Children's Hospital
Girish Dhall, MD
study chair · Children's Hospital of Alabama

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion